Embedded Files
Our Group
Our Group
Welcome to the Cancer Epigenomics Lab (CEL). We are focused on decoding the epigenetic "software" that becomes corrupted in cancer. Our lab explores the fundamental mechanisms of oncohistones, discovers new 'synthetic lethal' vulnerabilities in the DNA damage response, and engineers novel strategies to enhance CAR T cell therapies for hard-to-treat cancers. Our ultimate goal is to translate these molecular insights into the next generation of cancer treatments.
Dr. Rajesh Kumar Yadav, Principal Investigator
Dr. Rajesh Kumar Yadav, Principal Investigator
Dr. Rajesh Kumar Yadav is the Principal Investigator of CEL at the National Institute of Immunology (NII). After completing his PhD from the Indian Institute of Chemical Biology and Jadavpur University, Kolkata, he conducted his postdoctoral research at St Jude Children's Research Hospital in the USA.
CEL at NII
The research program at CEL is driven by the understanding that histones are not just packaging material for DNA, but dynamic signaling platforms that control gene expression in both cancer cells and immune cells. The lab's primary mission is to understand how these epigenetic mechanisms contribute to cancer pathogenesis and genomic instability. Utilizing cellular biology, molecular biology, and genomics, we, at CEL investigate the specific mechanisms underlying oncohistone mutations and their role in the DNA Damage Response (DDR) pathway. Furthermore, the lab explores new frontiers in cancer immunotherapy, aiming to enhance the antitumor potential of Chimeric Antigen Receptor (CAR) T cells by manipulating chromatin modifiers. The ultimate goal is to translate these fundamental discoveries into new cellular and chemotherapeutic agents for cancer management.
Copyrights © Cancer Epigenomics Laboratory, National Institute of Immunology
Page updated
Google Sites
Report abuse